

## c-MET biomarker, 9/15

**Biocept launched its c-MET amplification detection test.** This diagnostic assay, which uses a blood-based liquid biopsy, has the potential to help physicians identify patients who may be receptive to certain gastric and non-small cell lung cancer treatments.

Preliminary results from a study led by researchers at Massachusetts General Hospital and presented at the 2015 Gastrointestinal Cancers Symposium showed that a novel small-molecule c-MET inhibitor demonstrated promise in the treatment of c-MET-amplified GI cancers. In addition to targeting this mechanism in GI cancers, c-MET abnormalities (along with T790M mutations) are recognized as common mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in advanced NSCLC. Biocept launched an assay to detect the presence of T790M mutation in NSCLC patients in January 2015.

[\*\*Biocept\*\*](#), 858-320-8200